Sistema de Salut de Catalunya
Institut Català de la Salut
[Fazal ZZ] Medical College, Aga Khan University Hospital, National Stadium Road, Sindh, Pakistan. [Sen P] Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, India. [Joshi M] Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India. [Ravichandran N] Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. [Lilleker JB] Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. Neurology, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK. [Agarwal V] Mahatma Gandhi Mission Medical College, Navi Mumbai, Maharashtra, India. [Selva-O'Callaghan A] Unitat d’Inflamació i Autoimmunitat, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-12-19T13:11:05Z
2022-12-19T13:11:05Z
2022-12
COVID-19; Registries; Vaccination
COVID-19; Registros; Vacunación
COVID-19; Registres; Vacunació
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
HC is supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Article
Published version
English
Enquestes; COVID-19 (Malaltia) - Vacunació; Vacunes - Efectes secundaris; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Viral Vaccines; Other subheadings::Other subheadings::Other subheadings::/adverse effects; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas víricas; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios
Springer
Rheumatology International;42(12)
https://doi.org/10.1007/s00296-022-05157-6
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
